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Abstract
Chemotherapeutic strategies that target basal-like breast tumors are difficult to design without understanding their cellular
and molecular basis. Here, we induce tumors in mice by carcinogen administration, creating a phenocopy of tumors with
the diagnostic and functional aspects of human triple negative disease (including EGFR expression/lack of erbB, estrogen-
independent growth and co-clustering of the transcriptome with other basaloid models). These tumor strains are a
complement to established mouse models that are based on mutations in Brca1 and/or p53. Tumors comprise two distinct
cell subpopulations, basal and luminal epithelial cells. These cell fractions were purified by flow cytometry, and only basal
cell fractions found to have tumor initiating activity (cancer stem cells). The phenotype of serially regenerated tumors was
stable, and irrespective of tumor precursor cell. Tumors were passaged entirely in vivo and serial generations tested for their
phenotypic stability. The relative chemo-sensitivity of basal and luminal cells were evaluated. Upon treatment with
anthracycline, tumors were effectively de-bulked, but recurred; this correlated with maintenance of a high rate of basal cell
division throughout the treatment period. Thus, these tumors grow as robust cell mixtures of basal bipotential tumor
initiating cells alongside a luminal majority, and the cellular response to drug administration is dominated by the distinct
biology of the two cell types. Given the ability to separate basal and luminal cells, and the discovery potential of this
approach, we propose that this mouse model could be a convenient one for preclinical studies.
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Introduction
After subtracting ER+/PR+ and erbB2+ breast tumors, there
remains a miscellaneous collection of so-called ‘‘triple negative’’
tumors (15–20% of total tumors) that are ill defined with respect to
their molecular and cellular basis. The majority of these triple
negative tumors are also basaloid [1,2,3,4,5,6], as defined by their
relative over-representation of lineage-specific markers from the
basal mammary epithelial cell lineage, including cytokeratin 5
(KRT5) and EGFR. When analyzed, immunocytochemical
localization of cognate basal proteins shows that expression of
basaloid markers is heterogeneous, and restricted to a sub-
population of the total tumor cell population [6,7]. Luminal-
associated markers are also heterogeneously expressed, and
overall, the tumors therefore comprise mixtures of basal-like and
luminal-like cells [8].
Other breast tumor types have known molecular etiologies
offering effective therapeutic targets. The hunt is on for similar
targets in this tumor type, often by searching for consistent genetic
changes, either at the level of DNA mutations or transcriptional
signatures [2,9,10,11,12]. Studies have focused on the exclusively
triple negative breast tumors that arise in women with familial
Brca1 mutations. Mutations in Brca genes occur in approximately
1/5 triple negative tumors [13], and this pathway appears to be
affected in other ways (‘‘BRCA-ness’’ [2,10]) to create deficiencies
in DNA repair (and opportunities for synthetic lethal drug
development). As a marker of prevalence for this common
etiology, a signature associated with functional assays have shown
that homologous recombination is deficient in 2/3 triple negative
tumors [14], and an analysis of the prevalence of a DNA repair
signature has derived an approximately similar estimate [15].
With good reason, several groups have focused on the clear
association of Brca1 and p53 mutations with triple negative
human breast tumors to build models in mice [16]. However, it is
not likely that these mutations will cover all the molecular drivers
for this disease. To generate alternatives, we chose instead to focus
on recapitulating the dominant phenotype of mixed basal-luminal
cell populations, and to use the random mutational screen
afforded by carcinogen administration to select the tumor driver
that induces this phenotype. This offers a couple of advantages,
one is that carcinogen administration may provide a relevant
etiology for breast cancer, and the second is that random mutation
offers the opportunity for tumor driver discovery in the future.
Since basal and luminal cells are the usual progeny of basal-
associated stem cells [17,18], it was quickly assumed that these
tumors develop as the result of disordered stem cell growth and
differentiation. Whilst the importance of tumor stem cells to the
growth and metastasis of breast tumors in situ is not completely
understood, it is clear that these cells have different cellular
properties from the majority tumor. Thus, drug treatments that do
not substantially affect tumor growth can severely deplete the
tumor initiating cell population [19,20]. Other studies have shown
that cell minorities that are adapted to survive genotoxic,
metabolic or hypoxic stress (either with or without radiation or
chemotherapeutic treatment) may be important to tumor
recurrence [21,22,23]. A clear take home message from studies
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9of heterogeneous tumor cell populations is the importance of
understanding the separate and individual biology of the
constituent cell populations, to give insight into drug resistance
and tumor recurrence.
By choosing a phenotypic model of basal-luminal cell mixtures,
we assume that these mixtures are in some way important to the
tumor growth and development, rather than co-existing because of
a passive random process of differentiation. The model we have
developed for this purpose relies upon a classical rodent model of
breast cancer that has been used for several decades to test
potential breast tumor chemotherapeutics or preventative strate-
gies [24]. Thus, tumors induced in rodents by the polycyclic
aromatic hydrocarbon, 7,12-dimethylbenz(a)anthracene, (DMBA)
are fast-growing and contain mixtures of basal and luminal-like
cells. Here, we show that these ‘‘DTumors’’ (DMBA-induced
tumors) are functionally triple-negative, and therefore do not
depend upon the two pathways that are the known drivers of
human breast tumor growth. These tumors can be serially
passaged using low numbers of cells as tumor initiating
populations, and re-grow rapidly and consistently. The constituent
cell types can be separated by flow cytometry and individually
assessed for their functionality with respect to tumor propagation.
In contrast to the Brca1/p53 models described above, the cancer
stem cells are restricted to the basal cell fraction, their histology
and transcriptome are different, and tumor cells assemble Rad51-
associated foci in response to activation of DNA damage repair.
Furthermore, we show that the response of both cell types to
anthracycline administration is unequal, that the growth rate of
the basal minority is not affected by chemotherapeutics, and
tumors recur.
Results
Carcinogen-induced mammary tumors share the
principal features of human-basal-like breast tumors
The principal features of basaloid tumors are 1) over-expression
of mRNAs typically expressed by basal cells and 2) triple negative
character (ERa, PR-negative; erbB2 negative). We therefore
examined these criteria at the molecular and functional levels.
It has been shown before that DMBA-induced mouse tumors
comprise mixtures of basal and luminal-like cells [30]. We have
confirmed this using keratin expression (most often for this study,
cytokeratin 5 marking basal cells (KRT5) and cytokeratin 8 for
luminal cells; Fig. 1A). Typically, mouse models are not considered
to be good models of estrogen-dependent tumors (except those
that over-express ERa [31], and one strain bearing a mutant p53
allele [32]), mainly because, in contrast to human tumors, these
mouse tumors are estrogen-independent despite the presence of
ERa-positive cells [33]. To test whether DTumors depend upon
the estrogen-ERa growth axis, we therefore applied a functional
standard. 10 k tumor cells were transferred into fat pads of either
ovarectomized or normal recipient mice (Fig. 1B). This analysis
showed that tumor growth was not stimulated by estrogen, and
that the basal/luminal cell mixtures typical of these tumors were
estrogen-independent. (We attributed the failure to grow of 20% of
grafts to technical issues). Stains for ERa, and the canonical target
gene, PR, showed that although primary tumors were scored as
ERa-positive, there was little expression of PR (Fig. 1C). Grafts of
cells from primary tumors grew out slowly, and by the time of
sampling, the secondary (and subsequent generations of) tumors
were entirely ERa-negative (Fig. 1C). The elimination of residual
ERa expression during serial outgrowth suggests negative
selection, and indeed tumors grow faster in estrogen-low
environments than in normal mice (data not shown).
The last criterion of the triple negative description is that tumors
be erbB2-negative/EGFR-positive [2,3]. To test whether this was
true, tumor lysates were analyzed by Western blotting for their
relative expression of erbB2 (not detectable) and EGFR. EGFR
protein, and an activated downstream effector, pERK1/2, were
expressed at levels typical of normal mid-pregnant mammary
epithelium, where it is known to be necessary and sufficient for
growth induction [34] (Fig. 1D). These lysates were compared with
lysates from Neu/erbB2/HER1-induced mouse mammary tu-
mors, where the erbB2 signaling pathway is the tumor driver. The
level of EGFR expressed by DTumors was less than expressed by
Neu-tumors (approximately 1006less per mg total protein), but the
activation of p-ERK was much higher for (approximately)
corresponding receptor levels. This may relate to recent data that
shows a requirement for EGFR for other signaling events, such as
FGFR-mediated oncogenesis (also resulting in ERK activation)
[35]. By immunohistochemistry, activated phospho-EGFR co-
localizes with basal cells (shown by double staining with KRT5),
suggesting that these cells have more active, constitutive EGFR
signaling (Fig. 1D). This is consistent with recent studies showing
that EGFR signaling is required to induce and maintain normal
basal/myoepithelial mammary epithelial cells [36], and activated
in basaloid human tumors and cell lines [37]. For human basaloid
tumors, EGFR is typically expressed by subpopulations of tumor
cells (where it is also membrane associated), as summarized by
Badve et al. [2].
For BALB/c mice administered DMBA by gavage, most tumors
have a remarkably consistent appearance by histological criteria
(Fig. 1A; out of 19 analyzed, 17 were KRT5-positive), and are
described as adenocarcinomas with acinar differentiation [38]. To
test their phenotype by genetic means, we evaluated their
characteristics and relatedness by transcriptional profiling. To do
this, we compared DTumors (induced by orogastric gavage;
KRT5-positive) with tumors induced by intraperitoneal injection
of DMBA into BALB/c mice (see Methods; typically undifferen-
tiated adenocarcinomas; KRT5-negative; Fig. S1). This cohort
therefore arises in the same strain, using the same carcinogen, to
provide a contrasting phenotype in the same strain background.
Samples of primary tumors, together with tumor strains at
different generation numbers, were submitted to the Perou lab
for analysis, as per Herschkowitz et al [30]. When both tumor
types were co-clustered with a reference library of 122 tumor
samples, arising in various mouse breast tumor models [30],
samples designated as KRT5+ clustered together with other
basaloid tumor models (Fig. 2A–C), and those designated as
KRT5- clustered together with luminal models, such as transgenic
MMTV-neu-induced tumors (Fig. 2A and Fig. S2).
There are two principal signatures associated with basaloid
tumors, basal I (containing KRT5) and basal II (containing
KRT14) signatures. Heat maps of these two key signatures are
shown in Figs. 2A–C. The expression of the KRT5 signature was
consistent across the basaloid mouse models analyzed (Brca1/p53
and Wnt1, alongside DMBA-induced tumors in FVB mice and
DTumors induced in BALB/c model, this study, Fig. 2B).
Interestingly, the core KRT14 signature divided the Brca1/p53
and Wnt cohorts into two types, and suggested that the DTumors
fall into the KRT14-low subtype (Fig. 2C).
To compare the relationships between the 10 BALB/c tumor
samples analyzed here, the KRT5 basal I signature was used to
conduct an unsupervised hierarchical clustering of five KRT5-
positive DTumors and five KRT5-negative tumors (Fig. 2D). The
diagnostic genes for this group (which include collagen17, BMP7,
Jagged2, Id4, ectodysplasin A, EGFLAM (an ECM component),
Iroquois homeobox4, P-cadherin and phospholipaseC e2) resolved
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PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e30979Figure 1. KRT5+ DTumors parallel human basal-like breast tumors by functional and molecular assay. (A) Mixed lineage tumors.1 9
primary tumors were double stained with lineage-specific markers (keratin 5, basal cells, stained red; keratin 8, luminal cells, stained green) and 17
primary tumors (90%) comprise $10% K5-positive cells, as well as K8-positive cells, indicating that these tumors are bi-lineal. Two representative
images from two different primary tumors are shown. Scale bar=50 mm. (B) Estrogen-independence. The appearance of palpable tumor masses was
measured after transplanting 10,000 tumor cells into either control or ovarectomized three-week old BALB/c recipients (representative of 3 strainso f
primary tumor). Re-growth of tumors is no different in recipients grafted at 3 weeks of age. Paraffin sections from tumors removed from
ovariectomized hosts were compared to tumors from normal hosts, by double staining for K5 (green) and K8 (red). There was no difference in their
basal/luminal constituent cell types. (C) Experimental tumors are ERa/PR-negative. Paraffin sections from normal virgin BALB/c mammary glands (MG),
together with an example of a primary tumor (Primary T) and a secondary tumor (Second T), were stained for ERa and PR, and counterstained as
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Consensus clustering (using the same gene set) generated 2 sample
groups that also broadly recognized the KRT5-positive and -
negative tumors; the exception was the KRT5-positive tumor
(D19) that was intermediate between the two groups by all
statistical assays.
Since the unsupervised clustering analysis separated Brca1/p53
tumors from DTumors, we asked whether the gene set that
distinguished Brca/p53 tumors from the rest of the group of 122
(excluding the DTumor series) was expressed by DTumors, and
found that it was not (data not shown). The histopathology of
DTumors is also dissimilar from Brca1/p53 mutant mouse
tumors. They do not share the high degree of nuclear
polymorphism, mitotic index (sometimes 80% of tumor cells),
inflammatory infiltrate, central necrosis and pushing margins that
characterize Brca1/p53 tumors (described in detail in Fig. S3).
Since histopathology is usually related to molecular etiology, this
data is also consistent with a different molecular basis for
DTumors.
Loss of Brca1/p53 function results in a specific lesion in
homologous recombination (HR), one of the pathways activated in
response to DNA damage. Molecular analysis has shown that
Brca1 is required to assemble DNA repair-associated nuclear foci,
containing Rad51 [39]. In fact, the lack of assembly of Rad51-
positive nuclear foci can be used to test the status of HR-mediated
DNA damage repair [14]. To test directly whether DTumors are
deficient for homologous recombination, cells from DTumors
were cultured for 2 days, exposed to 10 Gy irradiation, and tested
6 hours later for their assembly of Rad51-associated nuclear foci,
as per [14]. Both normal and DTumor cells accumulated H2AX
(Fig. 2E) and Rad51-associated nuclear foci (Fig. 2F), suggesting
that this DNA damage pathway is likely intact. This molecular
assay also supports the hypothesis that DTumors are a distinct
type of basaloid tumor compared to Brca1/p53 tumors.
Purification of basal and luminal cell-enriched
populations from DMBA-induced tumors
To establish whether the heterogeneity of these tumors is the
result of differentiation of a bi-potential tumor cell, rather than the
recruitment of host tissues to a tumor microenvironment, we
transplanted tumor cells into fat pads of ubiquitously fluorescent-
GFP tagged recipients (Fig. S4), either without or with endogenous
epithelium (ie. ‘‘cleared’’ or left intact). This experiment was
designed to compare tumor cell outgrowths in the presence and
absence of local endogenous epithelium, to test whether normal
cells could infiltrate and significantly contribute to tumor
outgrowths. By either flow cytometric analysis or immunostaining
analysis, epithelial tumor cells were GFP-negative, confirming that
both lineages in DMBA-induced tumors derived from tumor cells,
though these tumors clearly draw on their host for the recruitment
of endothelial and leukocyte accessory cells.
To separate the basal and luminal-type tumor cells, we first
applied a standard method for discriminating normal basal and
luminal mammary epithelial cells (cell surface expression of CD49f
and CD24; [25]), but found that, despite their molecular
similarities, this protocol offered little resolution. However, the
cell surface antigen EpCAM, in combination with CD49f
(reported originally by Lim et al [40] as a means to separate
human tumor cells), provided robust discrimination (for at least 6
separate tumors, Fig. 3B and S5A; luminal cells are EpCAM
hiC-
D49
lo and basal cells are EpCAM
loCD49
hi). Though these are two
distinct populations, the overlap of expression of these cell surface
markers is high enough that neither alone is sufficient to
discriminate the two groups of cells. Thus expression of CD49f
is approximately 56 higher in basal compared to luminal cells,
and EpCAM is 76 higher in luminal compared to basal cells.
MMTV-neu tumors do not contain a similar basal cell population,
either by immunohistochemistry (Fig. 3A) or flow cytometry
(Fig. 3B).
When each population was tested (by ‘‘cytosplat’’) for expression
of luminal and basal markers in basal and luminal fractions
respectively, the purification was .99% for normal populations,
and .99% for the luminal cell component of tumors, dropping to
90–95% for the basal cell compartment (Fig. 3C). The basal cell
component of primary tumors varied from 5–30% of the total
epithelial cell population.
To evaluate the differentiation potential of each population, the
luminal and basal fractions from normal and tumor cell
populations were transferred to culture, allowed to grow for 4
days and stained for their expression of lineage markers. Normal
luminal cells in these culture conditions do not ‘‘retro’’-
differentiate to express basal cell markers (Fig. 3D), whereas the
bipotency of the basal cell fraction is associated with the
appearance of more than 30% of cells expressing luminal cell-
associated markers (after 4 days in culture). When DTumor cells
were transferred to culture, a similar pattern was observed, where
the luminal cells did not express basal markers, but basal cells
(though only 90% pure) expressed luminal cell markers. In other
words, these results are consistent with the suggestion that the
potential for genomic plasticity is not significantly affected by the
tumorigenic phenotype.
Functional tumor-initiating cells co-purify with the basal
tumor epithelial cell population
To directly address whether either cell population could initiate
tumor growth after isografting, cell fractions purified by flow
cytometry were transplanted into cleared fat pads at limiting
dilutions (Table 1). Total cell populations were compared to
luminal and basal cell subpopulations. All the tumor initiating cell
activity was associated with the basal cell fraction population (and
could be retrieved quantitatively from that fraction). Thus, for 26
recipient mice transferred with various numbers of basal cells
(totaling 10 520 cells), there were 9 tumor takes. For 24 recipient
mice transferred with luminal cells (totaling 23 400 cells), there
were no tumor takes.
After flow cytometric analysis, the overall tumor initiating cell
(TIC) frequency was approx 1 in 5000 cells (for the primary
tumors). In secondary tumors (that are ERa-negative (Fig. 1C) and
fast-growing (Fig. 4A)) the frequency of TICs increases, but the
tumor initiating activity remains focused entirely in the basal
indicated with either K5 (basal) or a DAPI nuclear stain. (The specificity of the anti-PR-A staining procedure is illustrated; Fig. S7). (D) EGF signaling
receptor expression. To evaluate expression of erbB2 and EFGR1, together with a downstream effector of EGFR1, p-ERK1/2 (and total ERK1/2) in four
primary tumors (DMBA D1, D18, D19, and D21), tumor tissue lysates (20 mgs) were compared with tumor tissue lysates from erbB2/neu transgenic
mice (with 10.0, 4.0 and 2.0 mgs total protein), and with mammary gland from mid-pregnant and virgin mice. Vinculin was used as a loading control.
Immunohistochemical staining for pEGFR in paraffin sections from normal mammary glands and tumors confirmed and extended the Western
blotting results. Cell surface-associated pEGFR is typical of basal cells in normal mammary glands and this cell type-specific expression pattern is
conserved in basaloid tumor cells. (Note that the green stain in the lumens is an artifact associated with sticky luminal secretions; panels C and D).
doi:10.1371/journal.pone.0030979.g001
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e30979Figure 2. DMBA-induced KRT5+ mammary tumors express a basal signature. (A). To test the relatedness of tumors by transcriptional
profiling, we compared samples of DTumors representing the two tumor classes (the specifics of these samples are shown in (D), KRT5+ DTumors and
KRT5- DTumors) with a group of 122 reference tumors described by Herschkowitz et al [30]. Excerpted here are the two key basaloid signatures,
keratin5 basal I signature (B) and keratin14 basal II signature (C). The three principal groups of mouse basaloid tumors known to date (MMTV-Wnt1,
Brca1/p53 and these DTumors) are indicated in different colors, forming clades that are related by their basal I K5 signature and differentiated by their
basal II K14 signature. For comparison, another group of DMBA-induced tumors induced in BALB/c mice by intraperitoneal injection (five KRT5-
DTumors; luminal tumors that are KRT5-negative, see Methods) co-clustered with luminal tumors developing in transgenic strains (Fig. S2). D) Robust
serial regeneration. To compare these two DTumor groups with each other, these 10 tumors (five KRT5-positive basaloid tumors and five KRT5-
negative tumors) were compared using the essential basal I signature (comprising 13 genes; LHS panel; Herschkowitz et al [30]), together with an
unbiased consensus clustering analysis (RHS). Primary tumors were numbered (D1, D2 etc), and samples of each were taken at different passage
numbers labeled as superscript (secondary D1
2 and tertiary D1
3 etc), to test the relatedness between samples and between generations. E–F) Assay of
Brca1-dependent initiation of homologous recombination DNA repair. Cultured cells from either normal mammary gland or a DTumor were cultured for
2 days, and irradiated with 10 Gy, 6 hours prior to imunohistochemical staining for cH2AX (green) and DNA (blue) (E; to illustrate the cellular
recognition of DNA damage), and the activation of homologous recombination-mediated DNA repair (F; assembly of Rad51-associated foci, Rad51,
green; DNA, red). Scale bar=10 mm.
doi:10.1371/journal.pone.0030979.g002
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in 1600 basal cells, to approx 1 in 70–300 basal cells (increasing 5–
206).
The tumor phenotype is stable over several generations
The evaluation of the efficacy of chemotherapeutics for the
prevention and treatment of primary carcinogen-induced
tumors has previously been limited by the long latency of
tumor development in response to DMBA (.200 days; [27]),
and the inefficiency of a model with a low penetrance
phenotype. However, we have exploited the fact that the
primary tumors grow quickly after they develop. Thus, we tested
how many cells were required to get rapid and consistent tumor
development, and whether the tumor phenotype changed with
serial regeneration.
Primary tumors were dissociated, and 10 k cells were re-
inoculated into cleared fat pads. When tumors re-grew, the
passage was repeated to generate a sequential series (Fig. 4A–C).
The first passage of tumor cells showed considerable mouse-mouse
heterogeneity in the rate of re-growth (onset 50 days, up to 4
months and beyond). However, subsequent passages grew back at
a rapid and consistent pace, starting in only 20–30 days, with
100% take rate for 10 k cells. The tumors that grew up showed
highly reproducible proportions of each cell type (ratios varied
from 4–8:1 luminal: basal cells), both from mouse to mouse (data
not shown) and from generation to generation (Fig. 4B and C; also
reflected in the microarray data shown in Fig. 2).
We compared whether tumors that re-grew from limiting
dilutions of purified subpopulations were different from those that
re-grew from total (Lin-) mixed cell populations. The source of
Figure 3. Purification of basal and luminal cell fractions from DMBA-induced mammary tumors. (A) Immunohistochemical stain of cell
type specific markers (as indicated in Fig. 1), and Ki67 (mitotic marker), in the following tissues prior to dissociation; normal 12 week-old mammary
glands, a DTumor, and an MMTV-neu induced mammary tumor. Scale bar=50 mm. (B) Flow cytometric separation of cells from BALB/c mammary
glands and DTumors using immunophenotyping antibodies, EpCAM and CD49f. Mammary epithelial cell populations from normal glands and
DTumors divided into two subpopulations, an EpCAM
+/CD49f
low/2 luminal (L) population, and an EpCAM
+/CD49f
high basal (B) population. The
specifics of flow cytometric analysis are described in Fig. S5. (C) Immunostaining of the sorted cell fractions shown in Panel B was used to establish
the relative purity of each ‘‘luminal’’ or ‘‘basal’’ cell fraction: K5 (blue), a-SMA (green), and K8 (red) (percentages are reported in the results). Scale
bar=50 mm. (D) Purified fractions of basal and luminal cells from either normal mammary gland or DTumors were cultured for 4 days and stained as
for panel (C). Only basal cell fractions differentiate to both cell types (illustrating their bipotency). Compared to normal cells, tumor cells tend to co-
express both keratin markers and lose their fate specification in cultures. Scale bar=50 mm.
doi:10.1371/journal.pone.0030979.g003
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phenotype, and re-established the original diversity of luminal
and basal cells, as measured by flow cytometry and keratin-
immunophenotyping (Fig. 4D). We deduce that even after serial
regeneration from limiting dilutions of cancer stem cells
(presumably clonal), the re-growth activity remains focused in
the basal cell fraction, and these cancer stem cells recreate a
characteristic and robust diversity of mammary epithelial cells.
The basal-like cell fraction is relatively chemo-resistant
To evaluate the response of this model to a chemotherapeutic
currently in use to treat this subtype of tumor, mice with
established tumors were administered the anthracycline, doxoru-
bicin (Adriamycin
TM, a topoisomerase I inhibitor), and tumor
growth measured with calipers (Fig. 5A). A single administration of
doxorubicin prevented growth for 2 weeks, but subsequently,
tumors recurred, with a growth rate similar to pre-treatment rates.
To determine the individual cellular response, the mitotic index of
basal and luminal cells were separately evaluated 2 days and 2
weeks after doxorubicin administration using BrdU labeling for
2 hours prior to tumor harvest (Fig. 5B–F).
In untreated tumors, approximately 7% of total tumor cells are
dividing (Fig. 5C); when evaluated separately, the mitotic index of
luminal and basal cells was approximately 8.5% and 5.5%,
respectively (Fig. 5D). Since luminal cells constitute the majority of
cells (approx 2/3; Fig. 5E), 80% of dividing cells in a tumor are
luminal (quantified in Fig. 5F). Although the mitotic index of basal
cells is lower, these cells could not be described as quiescent. (This
claim is made with respect to the two most active periods of
growth for normal mammary gland growth, ductal outgrowth and
pregnancy, which contain 3–6% BrdU-positive cells). We
emphasize this, because chemo-resistance is often ascribed to
quiescent cell populations (since cytotoxic activity associated with
drug administration almost always relies on cell division).
Two days after chemotherapeutic administration, the mitotic
index of basal cells increased (Fig. 5B and D) and most of the
dividing cells were basal (Fig. 5B and F), while the mitotic index of
the K8-positive cell population was reduced by 80% (2% BrdU-
positive; Fig. 5D, quantification of Fig. 5B). The relative
proportions of cell types remained approximately constant
(Fig. 5B and E; confirmed by flow cytometric analysis, shown in
Fig. S6), and there was little enrichment for basal cells. We deduce
that the basal cells continue to divide and differentiate into luminal
cells to re-establish typical proportions of each cell type. After 2
weeks, the mitotic index of the luminal cell population was re-
established at pre-treatment levels (Fig. 5D and F), and the tumor
mass began to grow. (Note we found it difficult to demonstrate
classic apoptosis or necrosis (Fig. S3 and data not shown), and
conclude that there may be alternative routes of tumor
remodeling, such as autophagy, that are important in this case).
We conclude that basal cells are relatively resistant to this anti-
mitotic chemotherapeutic, and that tumor re-growth is correlated
with the lack of substantial effect of anthracyclines against this
subpopulation.
Discussion
We have shown that DMBA-induced breast tumors comprise
a majority of luminal-like cells that cannot serve to propagate
tumors after dissociation, together with a minority of basal cells
that can act as tumor-initiating cells. This lineage hierarchy
reflects the normal organization of mammary epithelial differ-
entiation, where basal cells serve as the stem/progenitor cell
type. The luminal-like cells are more sensitive to anthracycline
Table 1. Functional analysis of cancer stem cell activity in DMBA-induced mammary tumors.
Tumors Cell fraction % cells in fraction
No. cells
transferred
Take
rate
Frequency of TICs
(95% CI)
Primary tumor
D19
Total
(Lin-)
100 3200 2/4 1/4938
(1/1574–1/15488)
1600 1/4
Luminal 56.4 1600 0/4 zero
800 0/4
Basal 16.2 1600 3/4 1/1593
(1/589–1/4309)
800 1/4
Second generation tumor D19
2 Luminal 64 1300 0/4 zero
650 0/4
Basal 12.2 120 1/4 1/278
(1/67–1/1143)
40 1/4
Second
generation tumor D1
2
Luminal 70.2 1000 0/4 zero
600 0/4
Basal 7.0 100 1/2 1/70
(1/19–1/249)
10 2/8
The frequency of tumor initiating cells (TICs) was compared for the total cell population (designated Lin
2), and two cellular sub-fractions (luminal and basal cell
populations), using fat pad assay of limiting dilutions of cell suspensions. Three series of cell populations were used: Primary tumor-D19 (Fig. 2), a second
generation tumor-D19
2 (obtained from basal cell transplantation of primary tumor D19), and another second generation tumor-D1
2 derived from
transplantation of a different primary tumor, D1 (Fig. 2).
doi:10.1371/journal.pone.0030979.t001
A Phenotypic Mouse Model of Basaloid Breast Tumors
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e30979Figure 4. The tumor bi-lineal phenotype is stable over several generations and independent of tumor precursor cell. (A) Tumor re-
growth in serial transplantation was assayed over time, by palpation (generating a Kaplan-Meier curve; n=sample number), inoculating with the cell
numbers indicated. (B) Immunostaining of primary, secondary, and tertiary DTumors with anti-K5 (red) and anti-K8 (green) antisera. Scale bar=50 mm.
(C) The proportion of cells staining for each lineage marker in vivo (assayed from 3 separate tumors for each generation; 3 fields each) for each of the
primary tumor and two serially regenerated tumors (Second T and Third T). (D) Corresponding immunocytochemical analysis and flow cytometric
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administration of doxorubicin, basal cells do not stop dividing
(measured as the mitotic index of KRT5-positive cells; Fig. 5B,D
and F). However, since the proportion of each cell type is
different, and the majority of tumor cells are luminal cells
(Fig. 5E), it is not surprising that chemotherapeutics effective
against luminal cells can de-bulk these basaloid tumors.
However, it is also clear that without high efficacy against the
regenerative basal cell subpopulation, therapeutic regimens will
fail. Given our results, we propose that it may be possible to
forecast durable responses for patients who have been treated
with chemotherapeutics by independently scoring basal- and
luminal-specific mitotic indices. (Note that K5 and K14 appear
to be regulated differently in mouse and human; K5 is a
stringent basal marker in mouse and assorts between basal and
luminal cells in human, and the opposite may be true for K14 in
human; [4,40]).
Would this model be a significant addition to the models already
available for the evaluation of triple negative breast cancer? There
are a new wave of human xenograft models derived by serial
Figure 5. The basal cell fraction is relatively resistant to chemotherapeutics. (A) Tumor response to treatment with doxorubicin.
Dissociated, second generation tumor cells (D19 shown here; results representative of 3 strains; 10 k cell inoculae) were iso-grafted into cleared fat
pads, and the re-growth of tumors was observed by palpation and caliper measurement. Doxorubicin (single dose, 5 mgs/kg) was administered
when tumors were 5 mm diameter (indicated as day 0), and this cohort compared to controls. Though initially substantially responsive to
chemotherapy (2 days), after 2 weeks, tumor growth relapses. (B) Selective arrest of luminal cells after exposure to chemotherapeutic. The mitotic index
(measured by anti-BrdU labeling, see Methods) of basal (K5) and luminal (K8) cells was measured in untreated or doxorubicin-treated tumors (at the
indicated times, either 2 days or 2 weeks after administration). (C–F) The fraction of dividing cells (BrdU-positive) per total population was measured
during the treatment course (C, compare to growth rate of palpable tumor mass, panel A). The mitotic index for basal and luminal cell sub-
populations is measured separately (D). The proportion of each cell subtype is shown with respect to the total population (E; grey are luminal, K8-
positive, and black are basal, K5-positive; double negative cells (DN) stain for neither marker). The proportion of basal and luminal cells that make up
the dividing cell population during drug treatment and recovery are shown in panel (F).
doi:10.1371/journal.pone.0030979.g005
analysis of tumor cell populations from a primary tumor, for comparison with tumors regenerated from cell isografts of limiting dilutions of the cell
type indicated (Lin
2 and basal cell). Scale bar=50 mm.
doi:10.1371/journal.pone.0030979.g004
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disease in most gross aspects, except their interaction with immune
cells and the heterotypic host environment [41,42]. There are
clearly similarities and differences between the DTumor model we
describe here, and other rodent models of triple negative tumors,
that are summarized below. Both similarities and differences have
positive associations. Similarities tend to emphasize the basaloid
nature of these tumors and the relevance to the human disease;
differences reveal aspects that are unique to this tumor model, that
offer an alternative discovery platform.
Firstly, transcriptional profiling shows these tumors are basaloid
(falling into a class alongside BRCA1 and p53 mutant mouse
models), but distinct from them (with respect to a Brca1 signature).
However, of the two basaloid signatures, the K14 basal II
signature stratifies tumors arising in Brca1- or Wnt1- mouse
models; some have a strong K14 basal II expression, the other
weak. This carcinogen-induced model falls into the class with a
strong K5 basal I signature, but weak K14 basal II signature.
Though the significance of this is not yet known, several of the
core genes are known to have functional roles in mammary
tumorigenesis.
Secondly, immunocytochemical analysis shows this tumor
model comprises cells that separately express either basal or
luminal type cytokeratins. This is also typical of many (but maybe
not all) human basaloid tumors [43,44]. From the published data,
it is not easy to determine whether the separate and distinct
populations are always a feature of basaloid human tumors, since
double-stained immunohistochemistry, visualizing more than one
antigen for a given sample, is rarely presented. Furthermore, an
antibody against ‘‘CK5/6’’ is often used for clinical evaluation,
though it may not be the most reliable [45]. As a cell lineage
diagnostic, it does not clearly discriminate basal and luminal cells.
(These keratins tend not to be lineage-restricted, but more likely to
indicate hyperplastic cells of either lineage). Histologically, human
basaloid tumors often have pushing borders, significant lympho-
cytic infiltration, highly pleomorphic nuclei, medullary features,
and exceptionally high mitotic indices (measured by immunocy-
tochemical Ki67 assay) [2]. Though these features are well
represented in Brca1-p53 based models [46,47], they are not a
characteristic of DTumors (Fig. S3).
Thirdly, on the point of tumor etiology, the significance of
carcinogen exposure as an etiology for triple negative breast
tumors is not known. Typically, the relevance of environmental
exposure (for example, smoking) as an etiology for breast cancer
has been controversial [48]. Though carcinogen exposure, in
theory, should mutate genes at random, mammary tumors
induced by DMBA gavage of BALB/c mice are remarkably
homogeneous (by histological, molecular and transcriptional
criteria; note that DMBA induces much more diverse tumors in
FVB mice [30,49], as does carcinogen administration (NMU) to
rats [50]). This could imply a common molecular and/or cellular
origin, though these are not yet known (probably not p53 [51] or
Ras [52]). Our histological assay of homologous recombination
(assembly of Rad51-associated foci) suggests that this DNA repair
pathway is intact. However, this strain is known to be mutant for
DNA protein kinase (DNA-PK) [53,54], a key element of non-
homologous end-joining (NHEJ), which may have relevance for
the mutational rate and the ability to repair DNA in response to
anthracycline administration. It is of some interest that it is not yet
known whether the absence of Brca1 itself is the driver of tumor
growth (by an unknown mechanism), or whether mutations
induced by repair deficiencies are the source of the tumors. If
the latter is correct, it may be difficult to find a common etiology
amongst the genetic noise, and indeed the genomic studies to date
have yet to reveal a dominant, connected set of genetic origins.
Surprisingly, Varela et al [55] suggest that there are few genetic
changes in the DNA of Brca1-negative mouse tumors that are
consistent with a repair-deficiency, perhaps due to their over-
expression of DNA repair gene mRNAs [15,55,56].
Fourthly, it has not been conclusively demonstrated that tumor
stem cells are important to tumor growth in vivo. However,
intuitively, cells that can serve to regenerate the tumor majority
could become especially important after chemotherapeutic
treatment. We examined which of the two purified cell
populations could regenerate a tumor, and found that the
tumor-initiating activity co-purified with basal cells. This
contrasts with recently published examples of a luminal ‘‘plastic’’
cancer stem cell for Brca1/p53 mutant tumors. Thus, the earliest
disorders of transcriptional phenotype that were noticed in
precancerous breast from Brca1-mutant women showed up in the
luminal cell population, perhaps a surprising observation given
luminal cells are usually restricted to luminal fates, and these
tumors have a clearly basaloid signature. However, this origin
was confirmed in mouse studies, together with the co-purification
of tumor stem cells with the luminal-type tumor cell [40,47,57].
Also in support, mammary tumors arising in luminal cells with
floxed alleles of Brca1 and p53 showed cancer stem cell activity
associated with a CD29
hiCD24
med sub-population [57,58], and
these cells also express Nanog, a gene associated with plasticity
and totipotency. Note that Pajic et al [57] discarded the
hypothesis that TIC activity was drug-resistant (for Brca1/p53
mutant tumors) based on their lack of enrichment after drug
treatment. To our view, enrichment is not predicted if the tumor
stem/progenitor cell does not arrest, and we therefore vary in our
interpretation.
‘‘Plastic’’ luminal TIC activities have also been identified in
mouse basaloid Wnt1- and p53-induced breast tumors [59], using
CD61 as a luminal cell marker, and by our group, using the
canonical Wnt receptor, Lrp5 [60]. A plastic luminal stem cell may
also be inferred from the gene profiles of a Thy1
+ tumorigenic
fraction isolated from Wnt1-induced tumors [61]. Zhang et al.
[62] showed that a CD29
hiCD24
hi subpopulation isolated from
these p53 mutant tumors resembled a luminal progenitor cell type.
Fifth, our data suggests a refinement for the approach to
analyzing anthracycline resistance, namely to score chemothera-
peutic responses individually for basal and luminal cells. For
tumors that rely on basal cell minorities for regeneration after
treatment, un-stratified response rates could be particularly
misleading. Anthracyclines are commonly used to treat patients
with triple negative breast tumors, and can be highly effective (for
approximately 1/4 patients); however, patients with residual
disease have the worst disease-free survival outcomes [63]. Genetic
changes that are statistically linked to anthracycline resistance
have been associated with amplifications in 8q22. Further analysis
has shown that two common amplifications led to a deficiency in
nuclear trafficking or the suppression of apoptosis [9], which could
be reversed in cell lines in vitro. A basal cell-associated stress
response protein, aßcrystallin, has been shown to be associated
with chemo-resistance in human breast cancer patients [64]. In the
carcinogen-induced basaloid tumor model reported here, the
reason for the drug resistance of basal cells may be related to these
mechanisms.
This carcinogen-induced model has properties that both classify
it with basaloid models, and serve to distinguish it from others.
The phenotype of the tumors is relatively stable over many
generations, even when tumors are re-grown from limiting
numbers of basal cells. This is useful from a pragmatic point of
view, for providing consistency of drug response and tumor
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fascinating from a theoretical point of view, since it implies a
selective pressure for this combination of basal and luminal cells.
When tumors recur, they have a phenotype indistinguishable from
the untreated tumor; this is typical for breast tumor recurrence
[65]. We hypothesize that the proportion of luminal and basal cell
daughters is actively regulated and functionally important.
In conclusion, we have shown that the basal and luminal-like
cells that comprise these basaloid tumors have different chemo-
sensitivity. Given that the tumor initiating activity is entirely basal
restricted for this model, we propose that understanding basal cell
biology is key to effective targeting for this tumor type, and that the
two lineages can be separately evaluated using simple cytokeratin
markers. This basaloid breast cancer model, maintained entirely in
vivo, could provide a valuable and complementary tool to add to
the current models.
Methods
Ethics Statement
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the University of Wisconsin School of
Medicine and Public Health Animal Care and Use Committee
(Protocol Number: M01422). The University of Wisconsin’s
animal welfare assurance number on file with the Office for
Protection from Research Risks is A3368-01. The number of mice
used to perform this study was minimized, and every effort was
made to reduce the chance of pain or suffering.
Mice
The following strains of mice were used: C57BL/6-Tg(CAG-
EGFP)1 Osb/J (strain 003291, expressing EGFP ubiquitously,
driven by the b-actin promoter), FVB/N-Tg(MMTVneu)202-
Mul/J and BALB/c (Jackson Labs, Bar Harbor, ME).
Antibodies used for Immunofluorescence and Western
blotting
Methods for staining tumor tissue sections and sorted cells on
slides were as described [25]. Primary antibodies used for
immunofluorescence were: rabbit anti-keratin 5 (Covance, Madi-
son, WI), rat anti-keratin 8 (Troma-I) (Developmental Studies
Hybridoma Bank, University of Iowa), rabbit anti-ERa (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA), mouse anti-PRA
(hPRa7; [26]), mouse anti-GFP, mouse anti-phospho (Y
1068)-EGF
Receptor (Cell Signaling Technology, Danvers, MA), FITC-
conjugated mouse anti-a-smooth muscle actin (Sigma, St Louis,
MO), mouse anti-Rad51 (Calbiochem, San Diego, CA), anti
cH2AX (Upstate, Temecula, CA) and mouse anti-BrdU (Roche,
Indianapolis, IN). Nuclear DNA was counterstained with TO-
PRO-3 (Molecular Probes), for 10 minutes at room temperature.
Immunofluorescent stains were visualized on a confocal micro-
scope (BioRad MRC1024). The following antibodies were used in
Western blotting as probes: anti-EGFR1 (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA), anti-erbB2 (Calbiochem, San Diego,
CA), anti-p-ERK and anti-ERK (Cell Signaling Technology), and
anti-vinculin (Chemicon International Inc., Temecula, CA).
Dissociation of Normal Mammary Epithelial cells and
DMBA-induced Tumor (DTumor) cells
The preparation of primary mammary epithelial cells was as
described [25]. For tumor cell suspensions, the following
modifications were made; tumors were finely chopped and
digested for 1 hour, 37uC in supplemented Epicult-B (cat#05602
05602 and 05603, Stem Cell Technologies, Vancouver, CA)
supplemented with 5% fetal bovine serum, 300 U/ml collagenase
and 100 U/ml hyaluronidase (cat#07912, Stem Cell Technolo-
gies). After lysis of the red blood cells, tumor cells were directly
dissociated in 5 mg ml
21 Dispase II plus 0.1 mg ml
21 DNase I. A
suspension of single cells was obtained by filtration through a
40 mm mesh.
Induction of Tumors by Administration of DMBA, and
Isograft Procedures
Carcinogen-induced primary tumors were induced by admin-
istration of 661 mg DMBA (DMBA was dissolved in tricaprylin at
5 mg/ml, 0.2 ml/dose, (Sigma, St. Louis, MO); approximately
0.15 mmols/gbw per treatment) by orogastric gavage to female
BALB/c mice, once a week starting at 12–14 weeks. This well-
established protocol was originally described by Dan Medina,
Baylor College, TX, and was used in a prior study by our lab [27].
20 mice were administered DMBA using this protocol, and 14
mice developed one or multiple mammary gland tumors within 7
months.
The tumors arising in response to a different protocol, but
using the same mouse strain and carcinogen, were used as a
useful cohort for direct functional and molecular comparison.
Thirteen mice were administered DMBA by intraperitoneal
injection at 12–14 weeks old (0.01 mmol/gbw, 106less than the
gavage protocol); 10 mice developed mammary gland tumors
within 14 months. This protocol induced many types of tumors
(principally lung and liver, see [27]), but more interestingly for
this study, induced mammary tumors with a distinct histopathol-
ogy (not microacinar, and no expression of basal cell associated
cytokeratin5).
For serial transplantation experiments, tumors were dissociated,
and 5000–10000 single cells were isografted into cleared fat pads
as described [28]. To test the contribution of host cells to tumor
outgrowth, BALB/c tumor cells were transplanted into F1
C57Bl6(EGFP): BALB/c recipients, to ensure immuno-compati-
bility. Tumor initiating cell frequency was calculated using limdil
software (http://bioinf.wehi.edu.au/software/limdil).
Drug administration to mice with isografted tumors
Doxorubicin (Sigma, St Louis, MO) was dissolved in saline,
and when tumors were approximately 5 mm diameter after fat
pad inoculation, mice were administered doxorubicin (5 mg/
Kg) or vehicle, by intraperitoneal injection. To detect actively
proliferating cells in tumors, 100 mg/kg BrdU was adminis-
tered by intraperitoneal injection, 2 hours prior to tumor
harvest.
Flow cytometric analysis and sorting
Fluorescence-activated cells sorting (FACS) analysis was done
using the FACSVantage SE (BD Biosciences, San Jose, CA)
equipped with 633 nm and 488 nm lasers, and the following
antibodies: APC-conjugated anti-CD45 (Cat. 559864; clone
number 30-F11; 1 mg/ml), APC-conjugated rat anti-mouse
CD31 (Cat. 551262; clone number MEC13.3; 1 mg/ml), FITC-
conjugated CD49f (Cat. 555735; clone number GoH3; 30 ml/ml)
from BD Biosciences, and PE-conjugated EpCAM (Cat. 118206;
clone number G8.8; 0.5 mg/ml) from BioLegend (San Diego, CA).
Propidium iodide (2 mg/ml final concentration) was added
15 minutes before cell analysis. The gating procedures are shown
in Fig. S5 (details according to [29]).
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15,000–20,000 viable cells were seeded into Matrigel-coated 8
well-chamber slides (Nalge Nunc International, Naperville, IL),
and cultured for 4 days in DMEM/F12 (Invitrogen, Carlsbad, CA)
supplemented with 2% FBS (Harlan Laboratories, Indianapolis,
IN), 10 mg/ml insulin (Sigma), 100 U/ml Penicillin/Streptomycin
(Invitrogen), and 20 ng/ml EGF (R&D System, Minneapolis,
MN). To assess DNA damage (assembly of cH2AX) and the
activation of homologous recombination (Rad51 focus formation)
in DTumor cells, primary cultures of cells from either normal
mammary gland or DTumors were irradiated with 10 Gy, and
incubated for 6 hours before fixation and immunohistochemical
staining.
Microarray analysis
Total RNA was collected and processed according to Hersch-
kowitz et al [30]. RNA was assessed for quality as described, and
analyzed on Agilent Mouse Oligo Microarrays (G4121A) by the
Perou laboratory. Data was uploaded and normalized and
compared to the Gene Expression Omnibus dataset listed under
the series GSE3165, using the processes previously described. To
examine the relatedness of the two morphologically distinct tumor
types induced in BALB/cJ mice in response to DMBA, a set of 10
samples (five each of basaloid (KRT5-positive DTumors) and non-
basaloid tumors (KRT5-negative DTumors)) were compared by
consensus clustering and unsupervised hierarchical clustering
Multi-Experiment Viewer (MeV_4_5 v10.2). We used a core
signature of 13 basaloid genes, described by Herschkowitz et al
[30]. Samples were median-centered and then normalized
followed by average clustering using Euclidian distances.
Supporting Information
Figure S1 Different administration routes of the same
carcinogen (DMBA) induce different types of tumors.
Sections of tumors arising in response to the administration of
661 mg DMBA by intragastric gavage (A) or by intraperitoneal
injection of 70 mgs DMBA (B) were stained with H&E (top) and
lineage-specific markers, keratin 5 (red) and keratin 8 (green)
(bottom). The basaloid tumors (DTumors) arising in response to
orogastric administration of DMBA were microacinar adenocar-
cinomas, staining positive for keratin-5, whereas the most frequent
tumor arising in mice administered DMBA by the intraperitoneal
route were keratin-5 negative and less differentiated.
(TIF)
Figure S2 Comparison of the transcriptome of DTu-
mors and KRT5-negative BALBc tumors with a bank of
tumors from mouse models (previously described by
Herschkowitz et al [30]). The two tumor types that arise in
BALB/c mice in response to DMBA are shown on the overview of
the heat-map, the basaloid group (in green) and the luminal group
(in purple). Details of the KRT5-positive type I basal and KRT14-
positive type II basaloid signatures are outlined (and illustrated in
Fig. 2A–C). Samples designated as KRT5
+ clustered together, but
one (D19) was sufficiently plastic at the transcriptional level to
express both basal and luminal genes. The luminal signature,
boxed as (c), was highly represented in the KRT5-negative cohort
(and excluded from the basaloid tumor type) and these tumors co-
cluster with luminal tumors (including MMTV-expressing models
such as MMTV-neu and MMTV-PyMT). One third-generation
KRT5-negative tumor had a claudin-low signature. Detailed data
and label expansions are available on request.
(TIF)
Figure S3 Histopathology of DTumors (treated with
doxorubicin) and Brca1-p53 mutant mouse tumors. H&E
stained paraffin sections of a representative DTumor, either
untreated, or treated with doxorubicin for 2 days, or 2 weeks (as
per Fig. 5) are shown, to illustrate their microacinar substructure,
relatively lower stroma/interstitium with little evidence of
inflammatory cells, lower proportion of necrotic areas/cells, low
nuclear pleiomorphism and mid level mitotic index (typically
grade II tumors). In contrast, a representative Brca1/p53 mutant
tumor (illustrated by Molyneux et al [47]) shows higher rates of
necrosis, high level nuclear polymorphism, substantial inflamma-
tory infiltrate and high mitotic indices (not shown are their pushing
margins).
(TIF)
Figure S4 Only the stromal components are recruited
from host, not either of the epithelial cell subtypes. (A)
The experimental scheme to test for incorporation of cells from the
host mammary gland into tumors. All cells in the host are GFP-
positive, and isografted cells are unlabeled and transferred into
either a cleared fat pad (no endogenous epithelium) or a normal
mammary gland (with endogenous epithelium) to test whether
endogenous mammary epithelial cells (say the basal cells) could be
recruited to the growing tumor isograft, to generate the typical cell
mixture. (B) Representative flow cytometric analysis of tumors
growing in GFP-expressing recipients. Cells were stained for non-
epithelial markers (so-called Lin+; CD31, (most) endothelial cells;
CD45, (most) hematopoietic lineage), together with GFP (ex-
pressed by cells in the host fat pad). The quartiles represent cells
that separate as follows: top right, non-epithelial tumor-associated
cells derived from the host (Lin+ GFP+); bottom left, tumor
epithelial cells derived from transplantation (Lin2 GFP2 cells).
Epithelial cells recruited to the tumor from host are predicted to
appear in the bottom right quartile (together with any non-
epithelial cell types that turn out to be CD452, CD312). This
assay illustrated the massive infiltration of non-epithelial GFP-
positive cells to these tumors, and there was no difference between
the fraction of CD31/CD45-negative cells with or without
endogenous epithelium. (C) Visualization of GFP-positive cells in
tumors. To confirm that GFP-positive cells were not epithelial,
tumor sections were counterstained with luminal (K8, red) or basal
(K5, blue) epithelial cell markers. Far left, low power; other panels
are higher magnification (of area boxed); triple stained as
indicated, or single stains to show cellular detail. Scale
bar=50 mm.
(TIF)
Figure S5 Gating and description of flow cytometric
analysis and sorting. (A) More examples to display the typical
separation of luminal and basal cells from several DTumors, based
on their expression of EpCAM and CD49f. (B) The gating
procedures used to separate luminal and basal epithelial cells from
BALB/c mammary glands and DTumors. After gating out the
debris and cell doublets, dead cells and lineage positive cells (Lin
+)
were sequentially excluded by staining with propidium iodide, and
then CD45/CD31. The gating tree shows the proportion of events
that were filtered through sequential gates. Single stained normal
mammary gland epithelial cells were used as compensation
controls and the automated compensation procedure were used
with Diva Software. Cells were sorted with a 130 mm nozzle tip at
low pressure (12 psi), and cells and 4-way sample collection tubes
were maintained at 4uC.
(TIF)
Figure S6 Flow cytometric analysis of untreated and
doxorubicin-treated tumors. A representative cytogram of
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administration of doxorubicin) shows that the proportion of each
cell type is robustly maintained during treatment.
(TIF)
Figure S7 Demonstration of specificity of PRA staining.
Immunohistochemical staining for PRA in normal virgin (MG)
and ovarectomized BALB/c mammary glands, counterstained as
indicated with both lineage markers, K5 (basal) or K8 (luminal).
PRA staining is absent in ovarectomized glands, consistent with
the loss of estrogen-ERa signaling.
(TIF)
Acknowledgments
Many thanks to Kay Powell, our diligent undergraduate researcher, for
scoring of the immunohistochemical assays presented in this manuscript,
and to Joel Puchalski for his assistance with flow cytometry. Many thanks to
Dr. Charles M. Perou (Lineberger Comprehensive Cancer Center,
University of North Carolina at Chapel Hill), for analyzing gene expression
in these tumor samples, and for comparing their bioinformatics with his
assembled tumor resource (Fig. 2S). Thanks also to Dr. Christine Clarke
(University of Sydney, Westmead Institute for Cancer Research) for her
antibody to mouse PRA, and for her advice. We depend upon Dr. Andreas
Friedl (University of Wisconsin, Department of Pathology) for his expertise
and mentoring on breast cancer pathology. We appreciate the contribu-
tions of Gemma Molyneux and Matt Smalley (Institute for Cancer
Research, London), who provided us with examples of tumor sections from
Brca1/p53 mutant mouse mammary tumors [47].
Author Contributions
Conceived and designed the experiments: SK CMA. Performed the
experiments: SK. Analyzed the data: SK AR CMA. Contributed reagents/
materials/analysis tools: AR. Wrote the paper: SK CMA.
References
1. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer.
N Engl J Med 363: 1938–1948.
2. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, et al. (2010) Basal-like
and triple-negative breast cancers: a critical review with an emphasis on the
implications for pathologists and oncologists. Mod Pathol.
3. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, et al. (2008) Basal-like
breast cancer defined by five biomarkers has superior prognostic value than
triple-negative phenotype. Clin Cancer Res 14: 1368–1376.
4. Rakha EA, Ellis IO, Reis-Filho JS (2008) Immunohistochemical heterogeneity of
breast carcinomas negative for estrogen receptors, progesterone receptors and
Her2/neu (basal-like breast carcinomas). Mod Pathol 21: 1060–1061; author
reply 1061–1062.
5. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, et al. (2008) Meta-
analysis of gene expression profiles in breast cancer: toward a unified
understanding of breast cancer subtyping and prognosis signatures. Breast
Cancer Res 10: R65.
6. Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AH, et al. (2007) Breast
carcinoma with basal differentiation: a proposal for pathology definition based
on basal cytokeratin expression. Histopathology 50: 434–438.
7. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, et al.
(2009) Triple-negative breast cancer: distinguishing between basal and nonbasal
subtypes. Clin Cancer Res 15: 2302–2310.
8. Toft DJ, Cryns VL. Minireview: Basal-like breast cancer: from molecular pro-
files to targeted therapies. Mol Endocrinol 25: 199–211.
9. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, et al. (2010) Amplification of
LAPTM4B and YWHAZ contributes to chemotherapy resistance and
recurrence of breast cancer. Nat Med 16: 214–218.
10. Turner NC, Reis-Filho JS (2006) Basal-like breast cancer and the BRCA1
phenotype. Oncogene 25: 5846–5853.
11. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, et al. (2008)
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109:
123–139.
12. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, et al. (2009)
Complex landscapes of somatic rearrangement in human breast cancer
genomes. Nature 462: 1005–1010.
13. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, et al. (2011)
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple
Receptor-Negative Breast Cancer. Clin Cancer Res 17: 1082–1089.
14. Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, et al. (2010) A marker of
homologous recombination predicts pathologic complete response to neoadju-
vant chemotherapy in primary breast cancer. Clin Cancer Res 16: 6159–6168.
15. Rodriguez AA, Makris A, Wu MF, Rimawi M, Froehlich A, et al. (2010) DNA
repair signature is associated with anthracycline response in triple negative
breast cancer patients. Breast Cancer Res Treat 123: 189–196.
16. Michalak EM, Jonkers J (2010) Studying Therapy Response and Resistance in
Mouse Models for BRCA1-Deficient Breast Cancer. J Mammary Gland Biol
Neoplasia.
17. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, et al. (2006) Purification
and unique properties of mammary epithelial stem cells. Nature 439: 993–997.
18. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, et al. (2006)
Generation of a functional mammary gland from a single stem cell. Nature 439:
84–88.
19. Zhang M, Atkinson RL, Rosen JM (2010) Selective targeting of radiation-
resistant tumor-initiating cells. Proc Natl Acad Sci U S A 107: 3522–3527.
20. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, et al. (2009)
Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin
signaling. PLoS Biol 7: e1000121.
21. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, et al. (2009) Association of
reactive oxygen species levels and radioresistance in cancer stem cells. Nature
458: 780–783.
22. Lomonaco SL, Finniss S, Xiang C, Decarvalho A, Umansky F, et al. (2009) The
induction of autophagy by gamma-radiation contributes to the radioresistance of
glioma stem cells. Int J Cancer 125: 717–722.
23. Kunigal S, Lakka SS, Joseph P, Estes N, Rao JS (2008) Matrix metalloprotei-
nase-9 inhibition down-regulates radiation-induced nuclear factor-kappa B
activity leading to apoptosis in breast tumors. Clin Cancer Res 14: 3617–3626.
24. Mehta RG (2000) Experimental basis for the prevention of breast cancer.
Eur J Cancer 36: 1275–1282.
25. Badders NM, Goel S, Clark RJ, Klos KS, Kim S, et al. (2009) The Wnt receptor,
Lrp5, is expressed by mouse mammary stem cells and is required to maintain the
basal lineage. PloS One 4: e6594.
26. Mote PA, Arnett-Mansfield RL, Gava N, deFazio A, Mulac-Jericevic B, et al.
(2006) Overlapping and distinct expression of progesterone receptors A and B in
mouse uterus and mammary gland during the estrous cycle. Endocrinology 147:
5503–5512.
27. McDermott SP, Ranheim EA, Leatherberry VS, Khwaja SS, Klos KS, et al.
(2006) Juvenile syndecan-1 null mice are protected from carcinogen-induced
tumor development. Oncogene.
28. Liu G, Bafico A, Harris VK, Aaronson SA (2003) A novel mechanism for Wnt
activation of canonical signaling through the LRP6 receptor. Mol Cell Biol 23:
5825–5835.
29. Alexander CM, Puchalski J, Klos KS, Badders N, Ailles L, et al. (2009)
Separating stem cells by flow cytometry: reducing variability for solid tissues.
Cell Stem Cell 5: 579–583.
30. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, et al. (2007)
Identification of conserved gene expression features between murine mammary
carcinoma models and human breast tumors. Genome Biol 8: R76.
31. Jones LP, Tilli MT, Assefnia S, Torre K, Halama ED, et al. (2007) Activation of
estrogen signaling pathways collaborates with loss of Brca1 to promote
development of ERalpha-negative and ERalpha-positive mammary preneopla-
sia and cancer. Oncogene.
32. Lin SC, Lee KF, Nikitin AY, Hilsenbeck SG, Cardiff RD, et al. (2004) Somatic
mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse
mammary tumors with high frequency of metastasis. Cancer Res 64:
3525–3532.
33. Mastroianni M, Kim S, Kim YC, Esch A, Wagner C, et al. (2009) Wnt signaling
can substitute for estrogen to induce division of ERalpha-positive cells in a
mouse mammary tumor model. Cancer Lett.
34. Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, et al. (1999)
Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles
for EGF receptor ligands in mouse mammary gland development. Development
126: 2739–2750.
35. Bade LK, Goldberg JE, Dehut HA, Hall MK, Schwertfeger KL (2011)
Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires
activation of the epidermal growth factor receptor. J Cell Sci 124: 3106–3117.
36. Pasic L, Eisinger-Mathason TS, Velayudhan BT, Moskaluk CA, Brenin DR,
et al. (2011) Sustained activation of the HER1-ERK1/2-RSK signaling pathway
controls myoepithelial cell fate in human mammary tissue. Genes Dev 25:
1641–1653.
37. Hochgrafe F, Zhang L, O’Toole SA, Browne BC, Pinese M, et al. (2010)
Tyrosine phosphorylation profiling reveals the signaling network characteristics
of Basal breast cancer cells. Cancer Res 70: 9391–9401.
38. Yan H, Blackburn AC, McLary SC, Tao L, Roberts AL, et al. (2010) Pathways
contributing to development of spontaneous mammary tumors in BALB/c-
Trp53+/2 mice. Am J Pathol 176: 1421–1432.
39. Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and
BRCA2. Cell 108: 171–182.
40. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, et al. (2009) Aberrant luminal
progenitors as the candidate target population for basal tumor development in
BRCA1 mutation carriers. Nat Med 15: 907–913.
A Phenotypic Mouse Model of Basaloid Breast Tumors
PLoS ONE | www.plosone.org 13 February 2012 | Volume 7 | Issue 2 | e3097941. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, et al.
(2007) A new model of patient tumor-derived breast cancer xenografts for
preclinical assays. Clin Cancer Res 13: 3989–3998.
42. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, et al. (2011) Tumor grafts
derived from women with breast cancer authentically reflect tumor pathology,
growth, metastasis and disease outcomes. Nat Med 17: 1514–1520.
43. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, et al. (2002)
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with
poor clinical outcome. Am J Pathol 161: 1991–1996.
44. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, et al. (2004)
Expression of luminal and basal cytokeratins in human breast carcinoma.
J Pathol 203: 661–671.
45. Bhargava R, Beriwal S, McManus K, Dabbs DJ (2008) CK5 is more sensitive
than CK5/6 in identifying the ‘‘basal-like’’ phenotype of breast carcinoma.
Am J Clin Pathol 130: 724–730.
46. Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, et al.
(2007) Somatic loss of BRCA1 and p53 in mice induces mammary tumors with
features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad
Sci U S A 104: 12111–12116.
47. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, et al. (2010)
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors
and not from basal stem cells. Cell Stem Cell 7: 403–417.
48. Kellen E, Vansant G, Christiaens MR, Neven P, Van Limbergen E (2009)
Lifestyle changes and breast cancer prognosis: a review. Breast Cancer Res
Treat 114: 13–22.
49. Currier N, Solomon SE, Demicco EG, Chang DL, Farago M, et al. (2005)
Oncogenic signaling pathways activated in DMBA-induced mouse mammary
tumors. Toxicol Pathol 33: 726–737.
50. Chan MM, Lu X, Merchant FM, Iglehart JD, Miron PL (2007) Serial
transplantation of NMU-induced rat mammary tumors: a model of human
breast cancer progression. Int J Cancer 121: 474–485.
51. Jerry DJ, Butel JS, Donehower LA, Paulson EJ, Cochran C, et al. (1994)
Infrequent p53 mutations in 7,12-dimethylbenz[a]anthracene-induced mam-
mary tumors in BALB/c and p53 hemizygous mice. Mol Carcinog 9: 175–183.
52. Cardiff RD, Gumerlock PH, Soong M-M, Dandekar S, Barry PA, et al. (1988) c-
H-ras-1 expression in 7,12-dimenthylbenzanthracene-induced Balb/c mouse
mammary hyperplasias and their tumors. Oncogene 3: 205–213.
53. Collis SJ, DeWeese TL, Jeggo PA, Parker AR (2005) The life and death of DNA-
PK. Oncogene 24: 949–961.
54. Williams ES, Klingler R, Ponnaiya B, Hardt T, Schrock E, et al. (2009)
Telomere dysfunction and DNA-PKcs deficiency: characterization and
consequence. Cancer Res 69: 2100–2107.
55. Varela I, Klijn C, Stephens PJ, Mudie LJ, Stebbings L, et al. (2010) Somatic
structural rearrangements in genetically engineered mouse mammary tumors.
Genome Biol 11: R100.
56. Martin SA, Hewish M, Lord CJ, Ashworth A (2009) Genomic instability and the
selection of treatments for cancer. J Pathol.
57. Pajic M, Kersbergen A, van Diepen F, Pfauth A, Jonkers J, et al. (2010) Tumor-
initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient
mammary tumor cells in vivo. Cell Cycle 9: 3780–3791.
58. Shafee N, Smith CR, Wei S, Kim Y, Mills GB, et al. (2008) Cancer stem cells
contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary
tumors. Cancer Res 68: 3243–3250.
59. Vaillant F, Asselin-Labat ML, Shackleton M, Forrest NC, Lindeman GJ, et al.
(2008) The mammary progenitor marker CD61/beta3 integrin identifies cancer
stem cells in mouse models of mammary tumorigenesis. Cancer Res 68:
7711–7717.
60. Kim S, Goel S, Alexander CM (2011) Differentiation Generates Paracrine Cell
Pairs that Maintain Basaloid Mouse Mammary Tumors: Proof of Concept.
PLoS One 6.
61. Cho RW, Wang X, Diehn M, Shedden K, Chen GY, et al. (2008) Isolation and
molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast
tumors. Stem Cells 26: 364–371.
62. Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, et al. (2008)
Identification of tumor-initiating cells in a p53-null mouse model of breast
cancer. Cancer Res 68: 4674–4682.
63. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, et al. (2007) The triple
negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Clin Cancer Res 13: 2329–2334.
64. Ivanov O, Chen F, Wiley EL, Keswani A, Diaz LK, et al. (2008) alphaB-
crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in
breast cancer. Breast Cancer Res Treat 111: 411–417.
65. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, et al. (2003) Gene
expression profiles of primary breast tumors maintained in distant metastases.
Proc Natl Acad Sci U S A 100: 15901–15905.
A Phenotypic Mouse Model of Basaloid Breast Tumors
PLoS ONE | www.plosone.org 14 February 2012 | Volume 7 | Issue 2 | e30979